Core Insights - TeleVox has launched the Planned Outreach Program to enhance patient engagement for small practices, addressing the outreach gap in patient care [1][3] - The TeleVox Practice Edition platform has been recognized as the "Best Practice Management Solution" in the MedTech Breakthrough Awards, showcasing its effectiveness in improving healthcare delivery [1][5] Product Features - The Planned Outreach Program includes prebuilt, specialty-specific campaigns and templates for seasonal and recurring care needs, allowing practices to proactively plan outreach [2] - Features such as the Annual Campaign Planning and Smart List Builder facilitate targeted communication by leveraging past appointment data and patient contact lists [2] - Communication can be delivered via SMS or IVR, ensuring convenience for patients, while follow-up features help re-engage non-responsive patients [2] Market Impact - The Planned Outreach Program aims to democratize access to advanced engagement technology for small practices, enabling them to provide proactive care similar to larger health systems [3] - By improving patient follow-up care, such as vaccinations and annual checkups, the program is expected to enhance patient health outcomes and increase practice revenue [3] - The platform reduces manual tasks for staff, improving operational efficiency and allowing for a more personalized patient care experience [3] Company Background - TeleVox is part of WestCX within West Technology Group and has been recognized for its innovation in digital patient relationship management [5] - The company serves over 7,000 healthcare organizations, including hospitals and community health centers, focusing on effective patient engagement and communication [5] - TeleVox integrates its solutions with electronic health records (EHR) to support automated, personalized interactions with patients [5]

Core Points - CareCloud has surpassed the accelerated filer threshold with a public float of $85.1 million as of June 30, 2025, triggering new compliance requirements under SEC regulations [1] - The achievement is seen as a validation of CareCloud's growth trajectory and investor confidence, with a commitment to compliance and corporate governance emphasized by the Co-CEO [2] - The current audit firm cannot perform the required ICFR attestation, necessitating a change in auditors to ensure compliance [2] - CareCloud has initiated a process to engage a new audit firm capable of fulfilling the necessary services for fiscal year 2025 [3] Company Overview - CareCloud specializes in AI-driven healthcare technology solutions, helping over 40,000 providers enhance patient care while reducing administrative burdens and operating costs [4]

UnitedHealth Group and Memorial Sloan Kettering Cancer Center are locked in a contract standoff that threatens to interrupt treatment for thousands of cancer patients in the New York area https://t.co/ofM1JnhWVV ...

This Startup Built A Hospital In India To Test Its AI Software.https://t.co/8eWJDPE9ID https://t.co/pXG0XV1ZB0 ...

Shares of Apollo Hospitals, India’s largest healthcare services firm, surged to a record Tuesday after it announced plans to merge its digital health and pharmacy businesses and spin them off as a new listed entity https://t.co/OsN2L4Xz4M ...

ab 27 June 2025 Global Research China Healthcare Expert call takeaways: JDH, a rising competitor in drug retail O2O Meituan: a clear leader in drug retail O2O We invited an ex-Meituan manager of the drug retail business to discuss the pharmaceutical retail O2O (online-to-offline, or quick-commerce) market. According to the expert, Meituan was one of the first to start the O2O business in 2013 and is now China's largest O2O provider owing to its delivery capability and dispatch system advantages. To expand o ...

Group 1 - A-shares market showed strong performance with all major indices rising, including Shanghai Composite Index up 0.59%, Shenzhen Component Index up 0.83%, and ChiNext Index up 1.35% on the last trading day of June [1][2][7] - The total market turnover reached 15,172 billion, with over 4,000 stocks rising, indicating a broad-based rally [1][7] - In the first half of the year, small and mid-cap stocks outperformed, with over 3,700 stocks rising, and several sectors like AI models and new consumption gaining significant attention from investors [1][7] Group 2 - The military, pharmaceutical, and photovoltaic sectors led the gains on the last trading day of June, with notable stocks like Changcheng Military Industry and Huaren Health showing significant price movements [2][3] - The white wine sector experienced a notable surge, with stocks like JiuGuiJiu and SheDeJiuYe rising by 6.88% and 3.48% respectively, reflecting renewed investor interest [4][3] - The brain-computer interface sector also saw active trading, with a 5.17% increase in the sector, driven by developments from Neuralink and its ongoing clinical trials [5][6] Group 3 - The first half of 2023 saw major indices like the North Star 50 Index rising by 39.45%, indicating a strong market recovery [7] - Key sectors that attracted investment included AI models, humanoid robots, new consumption, innovative drugs, and solid-state batteries, with significant gains observed across these areas [7][8] - Structural opportunities are expected to dominate the upcoming earnings season, with a shift in active funds from pharmaceuticals and consumption towards technology and finance sectors [8]

Core Insights - Amazon's entry into healthcare has significantly disrupted the traditional pharmacy landscape, raising concerns for established players like CVS Health [1][3] - CVS Health is rebounding strongly in 2025, becoming one of the top performers in the S&P 500, with a focus on integrated care and leveraging its extensive physical presence [2][10] Group 1: Company Strategies - Amazon is leveraging its logistics capabilities and technology to redefine healthcare delivery, including AI-powered prescription fulfillment and at-home diagnostics [1][5][7] - CVS Health is capitalizing on its vast network of over 9,000 retail pharmacies and integrated services to provide coordinated care and improve patient outcomes [4][6] Group 2: Performance Metrics - CVS Health reported $95 billion in revenue in Q1 2025 and has achieved a year-to-date stock performance of 56%, ranking eighth in the S&P 500 [2][10] - In contrast, Amazon's stock has only risen by 1.8% year-to-date, placing it at number 262 in the S&P 500 rankings [10][9] Group 3: Financial Projections - The Zacks Consensus Estimate for CVS's 2025 earnings per share suggests a 12.7% improvement from 2024, indicating strong growth potential [12] - Amazon's 2025 EPS is projected to improve by 12.5% over the previous fiscal year, reflecting ongoing growth in its healthcare initiatives [14] Group 4: Valuation Comparisons - CVS is trading at a forward price-to-earnings ratio of 10.48X, which is above its five-year median, yet remains attractively valued compared to Amazon's 33.3X [15] - Amazon's current valuation is below its five-year median, suggesting potential for future growth but also indicating higher execution risk in its healthcare ventures [15][16]

BEIJING, June 30, 2025 (GLOBE NEWSWIRE) -- TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the “Company” or “TRX”), a China-based insurance broker, today announced it has completed the acquisition of 100% of issued and outstanding shares of Ucare Inc. (“Ucare”), the sole operator of China’s only cloud-based AI-driven hospital and health insurance risk management platform. The all-stock transaction, valued at US$150 million, marks a major milestone in TRX’s strategy to expand into in-hospital distribution channel ...

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] Value Score - The Value Score identifies attractive and discounted stocks using ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow, appealing to value investors [3] Growth Score - The Growth Score emphasizes a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [4] Momentum Score - The Momentum Score helps investors capitalize on price trends, utilizing factors like one-week price changes and monthly earnings estimate changes to identify optimal buying times [5] VGM Score - The VGM Score combines the three Style Scores to highlight companies with the best value, growth forecasts, and momentum, serving as a strong indicator alongside the Zacks Rank [6] Zacks Rank - The Zacks Rank is a proprietary model based on earnings estimate revisions, aiding investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +25.41% since 1988 [7][8] Stock to Watch: Henry Schein Inc. - Henry Schein Inc. is a leading global distributor of healthcare products and services, operating in 33 countries and serving various healthcare practitioners [11] - Currently rated 3 (Hold) on the Zacks Rank, Henry Schein has a VGM Score of A and a Value Style Score of A, with a forward P/E ratio of 15.06, indicating attractive valuation metrics [11][12] - The company has seen upward revisions in earnings estimates, with the Zacks Consensus Estimate increasing by $0.02 to $4.86 per share for fiscal 2025, and an average earnings surprise of 2.4% [12]